Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1 Receptor Agonists to Maridebart Cafraglutide in Adult Participants With Obesity or Overweight
Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
研究概览
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Amgen Call Center
- 电话号码:866-572-6436
- 邮箱:medinfo@amgen.com
学习地点
-
-
-
Ponce、波多黎各、00717
- 招聘中
- Puerto Rico Medical Research Inc.
-
-
-
-
Alabama
-
Pelham、Alabama、美国、35124
- 招聘中
- Cahaba Research, Inc.
-
-
Arizona
-
Chandler、Arizona、美国、85224
- 招聘中
- Arizona Clinical Trials
-
Sun City、Arizona、美国、85351
- 招聘中
- Epic Medical Research - Sun City
-
Sun City West、Arizona、美国、85375
- 招聘中
- Clinical Research Institute of Arizona LLC
-
-
California
-
Chula Vista、California、美国、91911
- 招聘中
- Peninsula Research Associates
-
Palm Springs、California、美国、92262
- 招聘中
- Desert Oasis Healthcare Medical Group
-
Rialto、California、美国、92377
- 招聘中
- Inland Empire Liver Foundation
-
San Diego、California、美国、92120
- 招聘中
- Apex Clinical Research
-
Santa Ana、California、美国、92701
- 招聘中
- Southern California Clinical Research
-
-
Florida
-
Gainesville、Florida、美国、32610
- 招聘中
- University of Florida Department of Medicine
-
Hialeah、Florida、美国、33012
- 招聘中
- Aga Clinical Trials
-
Margate、Florida、美国、33063
- 招聘中
- South Florida Clinical Research
-
Miami、Florida、美国、33165
- 招聘中
- New Horizon Research Center
-
Miami、Florida、美国、33173
- 终止
- Research Institute of South Florida
-
Mt. Dora、Florida、美国、32757
- 招聘中
- Adult Medicine of Lake County
-
Orlando、Florida、美国、32825
- 招聘中
- Florida Institute for Clinical Research
-
Orlando、Florida、美国、32801
- 终止
- Clinical Neuroscience Solutions
-
Port Orange、Florida、美国、32127
- 招聘中
- Progressive Medical Research
-
The Villages、Florida、美国、32162
- 招聘中
- Charter Research - The Villages
-
-
Georgia
-
Canton、Georgia、美国、30114
- 招聘中
- East Coast Institute for Research
-
Columbus、Georgia、美国、31904
- 招聘中
- Columbus Research Foundation
-
Johns Creek、Georgia、美国、30024
- 招聘中
- Nsc Research
-
Union City、Georgia、美国、30291
- 招聘中
- Rophe Adult and Pediatric Medicine/Sky Clinical Research Network Group
-
Woodstock、Georgia、美国、30189
- 招聘中
- North Georgia Clinical Research
-
-
Hawaii
-
Kapolei、Hawaii、美国、96707
- 招聘中
- Mel A. Ona, M.D., Incorporated
-
-
Idaho
-
Meridian、Idaho、美国、83646
- 招聘中
- Solaris Clinical Research
-
-
Illinois
-
Skokie、Illinois、美国、60077
- 招聘中
- Endeavor Health
-
Springfield、Illinois、美国、62704
- 招聘中
- Central Illinois Diabetes and Clinical Research, a Division of Prairie Education and Research Cooper
-
-
Kansas
-
Lenexa、Kansas、美国、66219
- 招聘中
- Johnson County Clinical Trials
-
-
Louisiana
-
Baton Rouge、Louisiana、美国、70808
- 招聘中
- Pennington Biomedical Research Center
-
-
Michigan
-
Southfield、Michigan、美国、48034
- 招聘中
- Great Lakes Research Institute
-
Troy、Michigan、美国、48098
- 招聘中
- Arcturus Healthcare, Public Limited Company, Troy Internal Medicine Research Division
-
-
Mississippi
-
Ridgeland、Mississippi、美国、39157
- 招聘中
- Sky Integrative Medical Center
-
-
Montana
-
Missoula、Montana、美国、59808
- 招聘中
- Montana Medical Research
-
-
Nevada
-
Las Vegas、Nevada、美国、89109
- 招聘中
- Excel Clinical Research
-
-
New York
-
New York、New York、美国、10029
- 招聘中
- Icahn School of Medicine at Mount Sinai
-
Rochester、New York、美国、14609
- 招聘中
- Rochester Clinical Research
-
-
North Carolina
-
Morehead City、North Carolina、美国、28557
- 招聘中
- Centricity Research Morehead City Specialty
-
Raleigh、North Carolina、美国、27609
- 招聘中
- Accellacare of Raleigh
-
Wilmington、North Carolina、美国、28401
- 招聘中
- Accellacare Research of Wilmington
-
-
Oklahoma
-
Chickasha、Oklahoma、美国、73018
- 招聘中
- Epic Medical Research - Oklahoma
-
Oklahoma City、Oklahoma、美国、73112
- 招聘中
- Lynn Health Science Institute
-
-
Pennsylvania
-
Beaver、Pennsylvania、美国、15009
- 招聘中
- Heritage Valley Multispecialty Group Inc
-
Duncansville、Pennsylvania、美国、16635
- 招聘中
- Altoona Center for Clinical Research
-
-
Texas
-
Austin、Texas、美国、78757
- 招聘中
- Pinnacle Clinical Research Georgetown
-
DeSoto、Texas、美国、75115
- 招聘中
- Epic Medical Research - DeSoto
-
Edinburg、Texas、美国、78539
- 终止
- South Texas Research Institute
-
Houston、Texas、美国、77043
- 招聘中
- Biopharma Informatic, LLC
-
Houston、Texas、美国、77089
- 招聘中
- Research Physicians Network, LLC
-
Houston、Texas、美国、77040
- 招聘中
- JCCT- Juno Northwest Houston
-
McAllen、Texas、美国、78503
- 招聘中
- Biopharma Informatic-McAllen
-
McKinney、Texas、美国、75071
- 招聘中
- Texas Institute of Cardiology
-
North Richland Hills、Texas、美国、76180
- 招聘中
- North Hills Medical Research
-
San Antonio、Texas、美国、78215
- 招聘中
- American Research Corporation
-
San Antonio、Texas、美国、78230
- 招聘中
- VIP Trials
-
San Antonio、Texas、美国、78229
- 招聘中
- Gastroenterology Clinic of San Antonio PA
-
Tomball、Texas、美国、77375
- 招聘中
- Northwest Houston Heart Center
-
-
Washington
-
Redmond、Washington、美国、98052
- 招聘中
- Eastside Research Associates Health Research
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Body Mass Index (BMI) ≥ 25 at screening.
- Weight loss of ≥ 10% on weekly GLP-1 RA.
- Stable body weight.
- Stable dose of GLP-1RA.
- Stable gastrointestinal (GI) tolerability.
- Contraception for females.
- Willingness to follow trial procedures for the duration of the trial.
Exclusion Criteria:
- Obesity induced by other endocrine disorders (ex: Cushing's syndrome).
- Previous or planned surgical, endoscopic or device-based treatment for obesity.
- History of malignancy.
- Type 1/Type 2 diabetes mellitus (DM).
- Family or personal history of medullary thyroid cancer.
- Previous participation in a Maridebart Cafraglutide trial.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:MariTide Arm 1
Participants will receive maridebart cafraglutide dosing schedule 1 during the treatment period. |
Maridebart cafraglutide will be administered via subcutaneous (SC) injection.
其他名称:
|
|
实验性的:MariTide Arm 2
Participants will receive maridebart cafraglutide dosing schedule 2 during the treatment period. |
Maridebart cafraglutide will be administered via subcutaneous (SC) injection.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Percent Change from Baseline in Body Weight at Week 68
大体时间:Week 68
|
Week 68
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Percent Change in Body Weight Prior to the Start of Weekly GLP-1RA at Week 68
大体时间:Week 68
|
Week 68
|
|
Percentage of Participants Maintaining ≥ 80% of the Body Weight Reduction Achieved with Prior Weekly GLP-1RA Treatment at Week 68
大体时间:Week 68
|
Week 68
|
|
Percent Maintenance of the Body Weight Reduction Achieved with Prior Weekly GLP-1RA Treatment at Week 68
大体时间:Week 68
|
Week 68
|
|
Plasma Concentration of Maridebart Cafraglutide at Week 68
大体时间:Week 68
|
Week 68
|
|
Number of Participants with Treatment-emergent Adverse Events and Serious Adverse Events
大体时间:Up to 84 weeks
|
Up to 84 weeks
|
合作者和调查者
赞助
调查人员
- 研究主任:MD、Amgen
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
IPD 共享时间框架
Data sharing requests relating to this trial will be considered beginning 18 months after the trial has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this trial.
IPD 共享访问标准
Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen trial/trials in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.